Press
September 13, 2021

LARVOL CEO Experiments with One Year in the Metaverse

Press
August 16, 2021

LARVOL CEO Experiments with One Year in the Metaverse

Author

On August 15, 2021, Bruno Larvol strapped on his VR headset and committed to spend the next year of his work life inside. As the self-proclaimed "CEO of the Metaverse," he will take no internal video meetings or conference calls, and will replace email and phone with “avatar to avatar” conversations.

SAN FRANCISCO, CA, August 16, 2021 - BUSINESS WIRE - LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, today announced an ambitious business experiment. Founder and CEO Bruno Larvol is now running the business exclusively from virtual and augmented reality for a complete calendar year. This effort is in partnership with VR/AR collaboration platform Spatial and VR rendering and animation firm M2 Studio.

On August 15, 2021, Larvol strapped on his VR headset and committed to spend the next year of his work life inside. As the self-proclaimed "CEO of the Metaverse," he will take no internal video meetings or conference calls, and will replace email and phone with “avatar to avatar” conversations. His team of 180+ will simply have to join him in the metaverse, a blanket term for the digital world emerging in virtual and augmented reality.

"The future of business is in the metaverse," Larvol says. "And we want to explore every angle of its use for workplace collaboration and for the future of cancer research and drug development."

Larvol will use a variety of devices, including the Oculus Quest 2 and HoloLens, to travel among virtual environments in the Spatial platform, some custom built by the team at M2 Studio, who specialize in creating extraordinary VR spaces.

LARVOL became Spatial's largest corporate user earlier this year when they announced the company's commitment to going "VR-first." As a remote company since 2004, LARVOL was well-positioned to experiment with this innovation in remote work. It turned out to be a great fit for their company culture, with a team of digital nomads spread across the globe. Fast forward to today, and LARVOL team members are each equipped with a VR headset so they can meet, collaborate, and even socialize as avatars.

An evangelist for both new technology and remote work, Larvol believes this extreme experiment is necessary to truly understand the wild west that is the metaverse and to take the company's use of the technology to the next level.

"If you're going to take a rocket to Mars, you first have to spend a year in the desert preparing for the voyage," Larvol says. "We are the first business colony on the metaverse, and we have to think like pioneers on a rocket ship to the future. We need to spend a year fully invested in the atmosphere of the metaverse, and I believe that starts with me."

Larvol also hopes to shine a spotlight on the possibilities virtual reality offers for companies in all industries willing to explore. At LARVOL, that includes the visualization of cancer data and the potential to convene top opinion leaders in oncology in VR.

"Doing business in virtual reality is not for the faint of heart," he admits. "It's a little like logging on to the internet in 1996, but the payoff is worth it. Having our office in the metaverse through Spatial gave us the proximity that we didn't know we were missing, and helps us connect and collaborate, even pushing the boundaries of how we navigate the world of technology with our customers."

Bruno will be sharing his yearlong experience on social media and through regular events, held in partnership with Spatial and M2 Studio. He hopes other business leaders will take the leap to explore the metaverse along with him, starting now.

Learn more at LARVOL.com/ceo-of-metaverse.

About LARVOL:

LARVOL supports the data and intelligence needs of the pharmaceutical and biotech industries with expert curated information. Solutions include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The VR-first, remote-always LARVOL team includes MDs, PhDs, and industry professionals around the globe who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis.

About Spatial:

Spatial enables an entirely new way of working together and eliminates the need for video conferencing and work travel. Spatial is headquartered in New York City, with offices in San Francisco and Kansas City. With Spatial, users can connect from all over the world and share ideas seamlessly using life-like avatars and knowledge work tools, unlocking a new level of productivity not confined by space.

About M2 Studio:

M2 Studio is a professional rendering and animation firm, specializing in creating spectacular virtual reality environments that merge cutting-edge visualization technology with creative expression to deliver tomorrow’s immersive spaces, today.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.